Hydroxymethylbilane synthase promoter (HMBS promoter) (HMBS promoter)

The porphobilinogen deaminase (PBGD) gene promoter is a regulatory DNA sequence that governs the expression of the HMBS gene, which encodes the third enzyme in the heme biosynthetic pathway [1]. This promoter is essential for maintaining adequate levels of PBGD, an enzyme responsible for converting porphobilinogen into hydroxymethylbilane [2]. The HMBS gene is unique in that it possesses two separate promoters: one that is constitutively active in all tissues (housekeeping) and another that is specifically active in erythroid cells [1, 4]. Deficiencies in PBGD activity, often resulting from mutations in the gene or its regulatory elements, lead to Acute Intermittent Porphyria (AIP), a condition characterized by the toxic accumulation of heme precursors [3, 4]. In therapeutic development, the PBGD promoter DNA is a critical component of gene therapy constructs designed to restore enzyme function in the liver of AIP patients [3]. Experimental therapies, such as AAV-mediated gene transfer (e.g., rAAV5-hPBGD), utilize these regulatory sequences to drive the expression of a functional HMBS transgene [3, 5]. By targeting the expression at the transcriptional level, these therapies aim to prevent the neurovisceral attacks associated with the disease [3]. Clinical monitoring of such interventions focuses on the normalization of urinary porphobilinogen and delta-aminolevulinic acid levels [4]. Safety considerations for targeting this DNA region include the potential for off-target integration and the induction of an immune response against the delivery vector [5].

Other names

Porphobilinogen deaminase promoterPBGD promoterHMBS gene promoter DNAHydroxymethylbilane synthase gene regulatory region

Gene replacement therapy